Virtual Library
Start Your Search
D.R.M. Silva
Author of
-
+
P1.01 - Poster Session with Presenters Present (ID 453)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Epidemiology/Tobacco Control and Cessation/Prevention
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.01-047 - Clinical Presentation and Outcome of Neuroendocrine Lung Tumors in a Brazilian Cohort from 2000 to 2016 (ID 5778)
14:30 - 14:30 | Author(s): D.R.M. Silva
- Abstract
Background:
Neuroendocrine lung tumors (NET) are rare and heterogeneous neoplasms. Typical carcinoids (TC) and atypical carcinoids (AC) have better prognosis and their treatment is mainly focused on surgery. Large cell neuroendocrine carcinomas (LCNLC) are commonly widespread at diagnosis. Here we present clinical characteristics and outcome of patients with TC, AC and LCNLC treated at AC Camargo Cancer Center (ACCCC).
Methods:
We selected 114 consecutive patients with TC, AC or LCNLC treated at ACCCC from 2000 to 2016. Demographic variables included individual data, diagnostic and treatment patters. Data was collected and processed to obtain outcomes and survival information. It was intended to obtain not only epidemiologic characteristics, but also to determine and confirm selected variables as prognostic.
Results:
Main demographic results are described in the Table below:
For the entire population, median progression free survival (mPFS) was 158.5 months. mPFS was not reached (NR) for TC and AC, with 5-year PFS 81% for TC and 84% for AC and 10-year PFS 69% for TC and 59% for AC; no Statistical Significance (SS) was found between TC and AC in mPFS (p=0,549). mPFS was worst, with SS, for age ≥65 years (158.5x61.5 months; p=0.018), staging ≥2 (NRx75.7 months; p=0,027), ECOG ≥1 (158.5x35.2 months; p=0.001), node positive disease (N0xN≥1: NRx33.9; p=0.001). Same tendencies were observed for TC, also with SS, but not for AC. Median overall survival (mOS) retained the same tendency: 5-year OS was 74% for TC and 55% for AC and 10-year OS was 74% for TC and 47% for AC. mOS was not reached. Age ≥ 65 years (p=0.001), ECOG ≥1 (p=0.001) and staging ≥ 2 (p=0.001) also were predictable for worst mOS.VARIABLES TC AC TOTAL NUMBER OF PATIENTS 64(56.1%) 24(21.1%) 88(100%) SEX MALE 53.1% 41.7% 45.5% FEMALE 46.9% 58.3% 54.5% MEDIAN AGE YEARS 56.35 53.74 57.48 CLINICAL STAGING I 83.9% 55.0% 76.8% II 4.8% 20.0% 8.5% III 6.5% 0.0% 4.9% IV 4.8% 25.0% 9.8% ECOG 0 71.7% 84.6% 76.4% ≥1 20.3% 15.4% 25.4% COMORBIDITIES YES 56.9% 65.2% 59.3% NO 75.4% 66.7% 73.1% SMOKING HISTORY YES 24.6% 33.3% 26.9% NO 75.4% 66.7% 73.1% OTHER MALIGNANCIES YES 32.8% 4.2% 25% NO 67.2% 95.8% 75% FAMILY HISTORY YES 59.4% 66.7% 61.4% NO 40.6% 33.3% 38.6% SURGERY YES 92.2% 79.2% 88.6% NO 7.8% 20.8% 11.4%
Conclusion:
This study demonstrates an epidemiologic descriptive outlook of neuroendocrine LC in a Brazilian population. Older age, worst performance and higher staging were prognostic for poor outcomes in survival.
